Mesoblast Appoints Teresa Montagut Head of Clinical Development
Analysis based on 9 articles · First reported Mar 11, 2026 · Last updated Mar 11, 2026
The appointment of Teresa Montagut to a key leadership role at Mesoblast is expected to positively impact the company's stock, as it signals a strengthened focus on clinical development and expansion of its cell therapy programs. This move could lead to increased investor confidence in Mesoblast's future growth prospects and product pipeline.
Mesoblast Limited, a global leader in allogeneic cellular medicines, announced the appointment of Teresa Montagut MD, PhD as the new Head of Clinical Development and Medical Affairs. Reporting to Chief Medical Officer Dr. Eric Rose, Montagut will lead Mesoblast's medical affairs organization, focusing on clinical collaborations, investigator-initiated trials, and enhancing clinical communications. Her role is critical for unlocking the value of Mesoblast's cell therapy programs in new pediatric and adult inflammatory conditions, including expanding the indications for its FDA-approved product Ryoncil. Montagut brings extensive experience from Regeneron Pharmaceuticals, Novartis, F. Hoffmann-La Roche===Genentech, and Atara Biotherapeutics, where she led various oncology and immunotherapy programs. CEO Dr. Silviu Itescu emphasized her commitment to scientific excellence and expertise in clinical trial execution as central to Mesoblast's strategy.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard